
Research shows that cost-plus pricing can lower drug costs dramatically, depending on where in the supply chain the markup is applied.
Second-generation antipsychotics (SGAs), while clinically better than their earlier counterparts, have been associated with dramatic weight gain, diabetes and an atherogenic lipid profile.





